Eppendorf grows faster than the market
During the first half of 2017, the Eppendorf Group achieved group sales of €327.9 million (prior-year period: €305.5 million). At 7.3% (6.6% when adjusted for currency effects), growth in sales lay above average market growth in the life science industry. Income from operations (EBIT) climbed 9.1% to €63.2 million (prior-year period: €58.0 million), amounting to an EBIT margin of 19.3% (prior year: 19.0%). All of the Eppendorf Group’s market regions and product groups contributed to this positive overall development.
Thomas Bachmann, President & CEO of Eppendorf AG, was very pleased at this positive development: “The mid-year result shows that we outperformed the market during the first half of this year. We are currently working on digitalizing our product portfolio and the connectivity of our devices with our new generation of networked products, which we launched on the market during the first six months of the year. We are assuming that our business will continue to develop positively overall for the whole year 2017 and we expect growth to be higher than the industry average.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
